Marvel Biosciences obtains U.S. patent for drug MB-204

Executive Summary

• Marvel Biosciences Corp. received a Notice of Allowance and issued U.S. Patent No. 12,570,656 B2 for its lead therapeutic candidate, MB-204.
• The patent covers broad "composition of matter" and methods of use claims for purine compounds used in treating disorders, representing the third major jurisdiction (following Japan and China) to grant such protection.
• MB-204 is a novel fluorinated analogue of the approved Parkinson's drug Istradefylline, showing preclinical efficacy in depression, autism (including Rett Syndrome), and Fragile X models.

Key Details

• Patent Details: U.S. Patent No. 12,570,656 B2 granted for "Purine Compounds for Treating Disorders."
• Scope of Protection: Broad composition of matter and methods of use claims. Composition of matter claims are noted as the strongest form of pharmaceutical patent protection, offering potential long-term market exclusivity.
• Strategic Context: This is the third major jurisdiction to grant a composition of matter patent for MB-204, following issuances in Japan (Feb. 3, 2026) and China (Aug. 18, 2025).
• Asset Profile (MB-204):
  • Novel fluorinated analogue of Istradefylline (an approved adenosine A2A receptor antagonist for Parkinson's Disease).
  • Demonstrated superior pharmacokinetics.
  • Completed preclinical toxicology testing.
  • Showed excellent preclinical efficacy in depression and multiple autism models, including Rett Syndrome.
  • Currently being tested in Fragile X models.
• Market Context: Approximately 1 in 36 children at age eight are diagnosed with autism spectrum disorder, highlighting the unmet medical need for new agents.
• Strategic Value: The enhanced intellectual property position supports business development goals, partnerships, licensing, and long-term shareholder value creation.

Notable Quotes

• "This is the third major jurisdiction that has granted us a composition of matter patent for our lead molecule MB-204... We are very pleased to be granted this patent in the U.S., which is critical to executing our business development goals. Strong intellectual property is one of those key components pharmaceutical partners want to see when looking to consecrate a deal with a company such as Marvel." — Rod Matheson, CEO